129 related articles for article (PubMed ID: 38284433)
1. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
Iyer GR; Darpo B; Xue H; Lecot J; Zack J; Bebrevska L; Weis W; Jones I; Drollmann A
Clin Pharmacol Drug Dev; 2024 May; 13(5):572-584. PubMed ID: 38284433
[TBL] [Abstract][Full Text] [Related]
2. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
3. A Thorough QT Study to Evaluate the Effects of a Supratherapeutic Dose of Sertraline on Cardiac Repolarization in Healthy Subjects.
Abbas R; Riley S; LaBadie RR; Bachinsky M; Chappell PB; Crownover PH; Damle B
Clin Pharmacol Drug Dev; 2020 Apr; 9(3):307-320. PubMed ID: 31777203
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
7. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
8. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
Stier B; Fossler M; Liu F; Caltabiano S
Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
[TBL] [Abstract][Full Text] [Related]
9. Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.
Olsson H; Petri N; Erichsen L; Malmberg A; Grundemar L
Clin Drug Investig; 2017 Sep; 37(9):873-879. PubMed ID: 28660498
[TBL] [Abstract][Full Text] [Related]
10. Concentration-QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval.
Hughes JH; Bertz R; Bhardwaj R; Donohue MK; Madonia J; Anderson MS; Morris BA; Croop RS; Liu J
CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1044-1054. PubMed ID: 38812357
[TBL] [Abstract][Full Text] [Related]
11. A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval.
Mendell J; Matsushima N; O'Reilly TE; Lee J
J Clin Pharmacol; 2016 Apr; 56(4):484-91. PubMed ID: 26239632
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis.
Burstein AH; Brantley SJ; Dunn I; Altstiel LD; Schmith V
Clin Pharmacol Drug Dev; 2019 May; 8(4):426-435. PubMed ID: 30934161
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 Clinical Study Evaluating the Effects of Cenobamate on the QT Interval.
Darpo B; Sager PT; Xue H; Kamin M
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):523-534. PubMed ID: 35182037
[TBL] [Abstract][Full Text] [Related]
15. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
16. A Randomized, Double-Blind, Placebo- and Positive-Controlled, Three-Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval.
Sahota T; Dota CD; Vik T; Yan W; Verheijen RB; Walker S; Li Y; Goldwater R; Ghiorghiu D; Mellemgaard A; Ahmed GF
Clin Pharmacol Drug Dev; 2021 May; 10(5):521-534. PubMed ID: 33400845
[TBL] [Abstract][Full Text] [Related]
17. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects.
Mueller MS; Sidharta PN; Voors-Pette C; Darpo B; Xue H; Dingemanse J
Orphanet J Rare Dis; 2020 Oct; 15(1):303. PubMed ID: 33109218
[TBL] [Abstract][Full Text] [Related]
18. A Phase 1 Thorough QT/QTc Study of Therapeutic and Supratherapeutic Doses of Belumosudil in Healthy Subjects.
Schueller O; Lohmer L; Xue H; Darpo B; Patel J
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1221-1232. PubMed ID: 35881051
[TBL] [Abstract][Full Text] [Related]
19. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
